On September 6, 2023, Quoin Pharmaceuticals Ltd. (the ?Company?) entered into an Exclusive License and Distribution Agreement, effective as of September 1, 2023 (the License Agreement), with Farma Mondo SA. Pursuant to the License Agreement, the Company granted to Farma Mondo an exclusive license under its Product Technology (as defined in the License Agreement) to commercialize, upon receipt of applicable regulatory approvals, pharmaceutical product QRX003 (in finished dosage form for human use) in Singapore. The foregoing license will be royalty-bearing, and the Company will retain all rights not otherwise licensed under the License Agreement.